JSTOR Daily

Treatment of Bacterial Osteomyelitis and Staphylococcus aureus Endocarditis and Single-Dose Therapy for Uncomplicated Neisseria gonorrhoeae Infections: An Overview

Cefonicid is a new second-generation cephalosporin that has broad-spectrum antibacterial activity, achieves high peak serum concentrations, and has a long half-life. The high serum concentration and ...
The New England Journal of Medicine

Treatment of Bacterial Endocarditis with Cephalothin

Side effects of cephalothin included mild rashes, fever and superficial thrombophlebitis. An excessive blood level (51 μg per milliliter) developed in a patient who had a serum creatinine of 2.2 mg ...
The New England Journal of Medicine

Treatment of Bacterial Endocarditis with Cephalosporin Derivatives in Penicillin-Allergic Patients — Report of Four Cases

Results of preliminary studies suggest that certain cephalosporin C derivatives may be useful in the treatment of bacterial endocarditis. 11–15 Both cephalothin and cephaloridine have the essential ...
JSTOR Daily

Management of Methicillin-Resistant Staphylococcus aureus Bacteremia

Staphylococcus aureus bacteremia and endocarditis are serious infections that demand prompt clinical attention to ensure good outcomes. Of foremost importance is identifying and managing the source of ...
Business Insider

Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for the treatment of Staphylococcus aureus bacteremia

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ...
Frontiers

Advances in the Antimicrobial Management of Infective Endocarditis

Infective endocarditis (IE) is an uncommon infectious disease, with an annual incidence ranging from 3 to 7 cases per 100,000 people per year in ...
Nasdaq

ContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including ...

YONKERS, N.Y., Feb. 24, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), ...
Medscape

Novel Antibiotics for the Treatment of Staphylococcus aureus

Linezolid Nosocomial pneumonia, cSSSI Oral and intravenous form available, bacteriostatic, not approved for catheter-related bloodstream infections, side effects include myelosuppression, ...
Nasdaq

ContraFect Announces First Patient Dosed in Pivotal Phase 3 DISRUPT Study of Exebacase as a Treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis

YONKERS, N.Y., Jan. 10, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), ...
Business Wire

Pherecydes Pharma Has Submitted An Application For The Approval Of A Phase I Clinical Study In Infective Endocarditis Caused By Staphylococcus Aureus

NANTES, France--(BUSINESS WIRE)--Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated ...
News Medical

Staphylococcus aureus: Study describes development of resistance to antibiotic for the first time

The Staphylococcus aureus bacterium is one of the commonest pathogens and can even cause sepsis. The new antibiotic dalbavancin is very effective against many bacterial pathogens. However, resistance ...